Could a cancer therapy tame multiple sclerosis? new trial launches
NCT ID NCT07224373
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new treatment called AZD0120 for people with multiple sclerosis (MS) that has not responded to other therapies. AZD0120 is a type of immune cell therapy (CAR-T) designed to target and reset the immune system. The study will enroll 24 adults aged 18-60 and focus primarily on safety and tolerability over two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AZD0120, a type of immune cell therapy (CAR-T cells) that targets two proteins (CD19 and BCMA) on immune cells
- What this could lead to
- If this treatment is safe and effective, it could offer a new way to control multiple sclerosis by resetting the immune system, potentially reducing relapses and progression.
- What could go wrong
- This is a very early (Phase 1b) and small trial with only 24 people, so safety and effectiveness are not yet proven. CAR-T therapy can cause serious side effects like cytokine release syndrome or infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
WITHDRAWNTucson, Arizona, 85719, United States
-
Research Site
NOT_YET_RECRUITINGAurora, Colorado, 80045, United States
-
Research Site
NOT_YET_RECRUITINGWashington D.C., District of Columbia, 20010, United States
-
Research Site
RECRUITINGSt Louis, Missouri, 63110, United States
-
Research Site
RECRUITINGNew York, New York, 10016, United States
-
Research Site
RECRUITINGNew York, New York, 10032, United States
-
Research Site
NOT_YET_RECRUITINGCleveland, Ohio, 44195, United States
-
Research Site
RECRUITINGSeattle, Washington, 98122, United States
-
Research Site
NOT_YET_RECRUITINGMilwaukee, Wisconsin, 53226, United States
-
Research Site
NOT_YET_RECRUITINGLiverpool, 2170, Australia
-
Research Site
RECRUITINGMelbourne, 3000, Australia
-
Research Site
NOT_YET_RECRUITINGMelbourne, 3004, Australia
-
Research Site
NOT_YET_RECRUITINGWaratah, 2298, Australia
-
Research Site
NOT_YET_RECRUITINGMontreal, Quebec, H3A 1A1, Canada
-
Research Site
WITHDRAWNLeipzig, 04103, Germany
-
Research Site
WITHDRAWNMagdeburg, 39120, Germany
-
Research Site
WITHDRAWNWürzburg, DE-97072, Germany
-
Research Site
WITHDRAWNCambridge, CB2 2QQ, United Kingdom
-
Research Site
WITHDRAWNLondon, SE5 9RS, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new rowing seat help veterans with paralysis row freely?
- Simple chin and neck exercises put to the test for MS swallowing problems
- Could a daily walk shield the brain's wiring in aging MS patients?
- Brain boot camp: can a memory-training program sharpen thinking in multiple sclerosis?
- The eyes as a window to the brain: can a simple scan monitor MS, Alzheimer's, and Parkinson's?
- Brain training without drugs: can imagining movement ease MS pain?